An agenda built through deep collaboration with our community to ensure every session delivers substance over soundbites. You’ll hear from true subject matter leaders via candid case studies, collaborative panels, and varied panel discussions —providing clarity on what’s driving success across the customer engagement landscape
- Reimagine commercialization with commercial, medical affairs and market access collaboration across an asset's lifecycle, with customer insights shaping decisions from the earliest stages
- Drive industry-leading customer engagement by combining organizational integration and agility with AI-powered personalization for a seamless experience that meets every customer where they are, ultimately ensuring innovations reach and benefit patients faster with greater impact
- Learn how two sales leaders built trust and drove adoption across their teams, from recruiting the right pilot champions to scaling AI into everyday practice
- Discover how AI-generated interaction insights are reshaping self-development, giving reps a clearer, more objective path to what's driving HCP behavior change
- See how organizations are using APEX* Pharma Sentiment Score to inform strategy in real-time, driving continuous improvement all while being able to benchmark against industry peers.
*ADVANCE AI Pharma Emotive IndeX
Â
Ryan Beaird, Senior Area General Manager, Bayer
Deanna Olson, Senior Area General Manager, Bayer
- Redefine customer interactions by shifting from rigid CRM journeys to intelligent platforms that adapt dynamically to context, timing, and intentÂ
- Drive commercial growth through AI segmentation capabilities that anticipate patient journeys and predict prescribing patterns before they occurÂ
Alicia Abella, Head of AI Product, Novo Nordisk
Darshan Joshi, Head of Commercial Technology Blueprint Transformation, USBU & OBU, Tadeka
Elizabeth Beringer, President, Real ChemistryÂ
- Strengthen patient relationships by shifting from channel-level fixes to a true operating model
- Maximize direct-to-patient value by treating this as a systems design challenge, not a content or technology gap
- Close the gap between initiatives that look strong on day one and models built to hold up as direct-to-patient relationships scale
Â
Silvi Haldipur, Head of Customer Experience Strategy and Human Centered Design, Novo Nordisk
Amy Turnquist, VP, the America's Operating Borad, Healthcare Businesswomen’s Association
 From prescription to patient journey: Orchestrate end-to-end value through data, technology and cross-functional alignmentÂ
- Deploy RWE and patient-outcomes data to reframe HCP perception, proving holistic care impact beyond clinical endpoints
- Equip MSLs, reps, and brand teams with role-specific, data-powered playbooks to deliver a unified value narrative across home care, decentralized diagnostics, reimbursement, and access
- Leverage data platforms to transform everyday patient behavior into commercial-ready evidence that bridges trial endpoints and lived experience
Â
Saket Malhotra, Global Head of Commercial Digital, BioMarin
Holly Valdiviez, Senior Vice President, Neuropsychiatry Franchise, Acadia Pharmaceuticals
Caroline De Marco, VP, Population Health Community Impact Ambassador, Genentech
- Discover how the Giants built a cross-channel customer feedback engine that informs strategy in real time, improving content from week to week in one of the NFLs biggest media markets
- Hear how the Giants build customer experiences that compete with entertainment, social media, and every other thing pulling for attention, and what that means for the modern HCP
- The blind spot in HCP targeting: Most targeting models are built on retrospective claims analysis — a record of where patients ended up, not how they actually experienced their disease. We'll examine why this backward-looking approach systematically misdirects commercial strategy.
- Clinical intent as the missing layer: Introducing clinical intent — a more holistic way to read disease experience and identify the right patient cohort before asking which HCPs to target, rather than reverse-engineering targeting from historical claims patterns.
- Operationalizing Patient First, Doctor Second: What this reordering means in practice — for data strategy, cohort definition, and how commercial teams should rethink the sequence of who they study first.
Scott Phillips, Vice President, Real World Data Diaceutics, Diaceutics
Interactive workshop 1: From AI experiments to commercial impact: how intelligent data ecosystems are reshaping the pharma value chain Â
- Harness AI-enabled infrastructure and governed data intelligence to accelerate the transition from experimentation into compliant, scalable commercial executionÂ
- Strengthen medical-commercial collaboration through intelligent, cross-functional data sharing that surfaces actionable insights and drives measurable field impact at every stage of the commercial journeyÂ
Interactive workshop 2: From siloed to seamless: How data connectivity unlocks the real-world consumer, patient, and HCP journey
- Healthcare and pharma marketers have more data than ever — yet the consumer, patient, and HCP journey often remains fragmented across disconnected 1st, 2nd, and 3rd-party sources
- This session explores how data connectivity, not just data volume, is the key to overcoming that fragmentation
- Attendees will learn how securely linking owned, partner, and external data sources creates a unified, longitudinal view of the journey — from awareness through diagnosis, treatment, and prescribing behavior
- The discussion will cover what effective data connectivity requires in practice, and how organizations can translate a connected view into sharper targeting, better measurement, and superior real-world business outcomes
- Accelerate strategic decisions by deploying AI analytics that filter out distractions and spotlight the precise signals forecasting HCP engagement quality and conversion opportunitiesÂ
- Amplify cross-functional collaboration by creating unified data architectures that transform disconnected touchpoints into one continuously updated view of the complete customer journeyÂ
- Eliminate the revision cycles that stall your commercial and medical teams through screening tools that cut approval timelines and get personalised content into the hands of field teams fasterÂ
- Build tiered approval frameworks that apply the right level of scrutiny to the right content, empowering your team to scale personalised, compliant customer engagement without the bottlenecks that slow impact
- Elevate engagement quality by fusing NBA precision with value-driven content strategies that address real customer priorities instead of relying solely on channel optimizationÂ
- Drive operational excellence by integrating omnichannel delivery, AI MLR acceleration and tiered approval systems into one cohesive personalization engine that scales impactÂ
- Map the structural parallels between underrepresented leadership pathways in pharma and underrepresented customer voices in the healthcare ecosystem — identifying the shared patterns of "fewer peers, fewer channels, more friction"
- Translate personal leadership strategies — built from navigating rooms with limited access or sponsorship — into concrete tactics for building trust and influence with underserved HCP and patient populations
- Co-create at least one practical, cross-functional approach (commercial, medical, or engagement) that teams can pilot to authentically reach a specific underrepresented HCP or patient segment
- Commit to a personal or team-level action step — walking away with both a peer network and a concrete next move to bring back to their organization
- Accelerate time-to-market for symposia content and capture HCP attention at the moment of highest engagement by producing targeted educational resources within days of data readoutsÂ
- Strengthen HCP relationships and boost engagement with relevant, compelling content at the exact moment it matters mostÂ
- Drive organizational agility by leveraging AI to harmonize fragmented data sources into connected strategic intelligence across all functionsÂ
- Strengthen customer engagement by designing connected journeys powered by AI-driven insights that predict and respond to evolving HCP needs in real timeÂ
- Accelerate decision-making by delivering on-demand, real-time analytics that enable medical and commercial teams to act faster without waiting for manual data requests or approvals
- Drive measurable business outcomes by translating shared insights into automated workflows that reduce time-to-action and improve consistency across functions
Anindita Sinha, VP, Commercial Operations, Shionogi
Preethi Ramesh, Director - Data Digital & Technology, Takeda
- Drive strategic alignment by leveraging AI-powered intelligence layers that grant appropriate visibility to medical and commercial teams while respecting access protocols
- Optimize cross-functional performance by building data-sharing frameworks that eliminate silos without breaching regulatory separation requirements
- Legacy segmentation models were built for a world where frequency equalled impact — but as HCP access tightens and attention shrinks, are your targeting assumptions accelerating disengagement rather than preventing it?Â
- The field team of the future looks less like a rep and more like a trusted advisor armed with real-time behavioural intelligence — what needs to fundamentally change in your capabilities, culture, and processes to make that a reality?Â
Is your omnichannel strategy just multichannel with better branding — or are you personalizing at scale?Â
- Most omnichannel models still push content based on assumed preferences rather than real behavioural signals — are you genuinely orchestrating HCP journeys, or simply delivering the same message across more channels and calling it personalisation?Â
- When response signals tell you your content, timing, or channel mix isn't working, how quickly can your organisation act on that — and is your current feedback loop fast enough to matter in a market where HCP attention is the scarcest resource?Â
- Maximise therapeutic value and patient outcomes by deploying AI-driven education strategies that deliver personalised, up-to-date authentic insights at the optimal moment in the care pathway.Â
- Inform smarter Next Best Action decisions by surfacing real-time, evidence-based clinical insights tailored to each physician's practice context and patient population.
- Accelerate organizational performance by embedding AI-enabled tools and role-specific intelligence that empower teams to scale meaningful, compliance-ready HCP engagement Â
- Build hybrid team structures that blend human expertise with agentic AI to scale consistent, outcome-led personalization across every HCP touchpoint
Pharma executives take the stage to define their biggest unsolved challenges and describe the perfect solution — if it existed. An open, on-stage session where end users set the agenda and solution providers listen. The ideal close after two days of content: reflect, identify the gaps, and look ahead.
- Define the right AI foundation by aligning architecture, investment priorities, and resource allocation to accelerate business value
- Establish scalable systems, governance, and operating models that enable organizations to move from pilots to enterprise-wide adoption
- Identify the most critical unmet challenges and explore how emerging technologies can close gaps and unlock future growth
Jaspreet Singh, Chief Customer Officer, Empower Pharmacy
Div Khetia, Vice President, Medical Affairs Channel Excellence and Medical Digital Health Solutions, Pfizer
- Reimagine commercialization with commercial, medical affairs and market access collaboration across an asset's lifecycle, with customer insights shaping decisions from the earliest stages
- Drive industry-leading customer engagement by combining organizational integration and agility with AI-powered personalization for a seamless experience that meets every customer where they are, ultimately ensuring innovations reach and benefit patients faster with greater impact
- Learn how two sales leaders built trust and drove adoption across their teams, from recruiting the right pilot champions to scaling AI into everyday practice
- Discover how AI-generated interaction insights are reshaping self-development, giving reps a clearer, more objective path to what's driving HCP behavior change
- See how organizations are using APEX* Pharma Sentiment Score to inform strategy in real-time, driving continuous improvement all while being able to benchmark against industry peers.
*ADVANCE AI Pharma Emotive IndeX
Â
Ryan Beaird, Senior Area General Manager, Bayer
Deanna Olson, Senior Area General Manager, Bayer
- Redefine customer interactions by shifting from rigid CRM journeys to intelligent platforms that adapt dynamically to context, timing, and intentÂ
- Drive commercial growth through AI segmentation capabilities that anticipate patient journeys and predict prescribing patterns before they occurÂ
Alicia Abella, Head of AI Product, Novo Nordisk
Darshan Joshi, Head of Commercial Technology Blueprint Transformation, USBU & OBU, Tadeka
Elizabeth Beringer, President, Real ChemistryÂ
- Strengthen patient relationships by shifting from channel-level fixes to a true operating model
- Maximize direct-to-patient value by treating this as a systems design challenge, not a content or technology gap
- Close the gap between initiatives that look strong on day one and models built to hold up as direct-to-patient relationships scale
Â
Silvi Haldipur, Head of Customer Experience Strategy and Human Centered Design, Novo Nordisk
Amy Turnquist, VP, the America's Operating Borad, Healthcare Businesswomen’s Association
 From prescription to patient journey: Orchestrate end-to-end value through data, technology and cross-functional alignment
- Deploy RWE and patient-outcomes data to reframe HCP perception, proving holistic care impact beyond clinical endpoints
- Equip MSLs, reps, and brand teams with role-specific, data-powered playbooks to deliver a unified value narrative across home care, decentralized diagnostics, reimbursement, and access
- Leverage data platforms to transform everyday patient behavior into commercial-ready evidence that bridges trial endpoints and lived experience
Saket Malhotra, Global Head of Commercial Digital, BioMarin
Holly Valdiviez, Senior Vice President, Neuropsychiatry Franchise, Acadia Pharmaceuticals
Caroline De Marco, VP, Population Health Community Impact Ambassador, Genentech
- Discover how the Giants built a cross-channel customer feedback engine that informs strategy in real time, improving content from week to week in one of the NFLs biggest media markets
- Hear how the Giants build customer experiences that compete with entertainment, social media, and every other thing pulling for attention, and what that means for the modern HCP
- Maximise therapeutic value and patient outcomes by deploying AI-driven education strategies that deliver personalised, up-to-date authentic insights at the optimal moment in the care pathway.Â
- Inform smarter Next Best Action decisions by surfacing real-time, evidence-based clinical insights tailored to each physician's practice context and patient population.
- Accelerate organizational performance by embedding AI-enabled tools and role-specific intelligence that empower teams to scale meaningful, compliance-ready HCP engagement Â
- Build hybrid team structures that blend human expertise with agentic AI to scale consistent, outcome-led personalization across every HCP touchpoint
Pharma executives take the stage to define their biggest unsolved challenges and describe the perfect solution — if it existed. An open, on-stage session where end users set the agenda and solution providers listen. The ideal close after two days of content: reflect, identify the gaps, and look ahead.
Â
- Define the right AI foundation by aligning architecture, investment priorities, and resource allocation to accelerate business value
- Establish scalable systems, governance, and operating models that enable organizations to move from pilots to enterprise-wide adoption
- Identify the most critical unmet challenges and explore how emerging technologies can close gaps and unlock future growth
Â
Jaspreet Singh, Chief Customer Officer, Empower Pharmacy
Div Khetia, Vice President, Medical Affairs Channel Excellence and Medical Digital Health Solutions, Pfizer
- Accelerate strategic decisions by deploying AI analytics that filter out distractions and spotlight the precise signals forecasting HCP engagement quality and conversion opportunitiesÂ
- Amplify cross-functional collaboration by creating unified data architectures that transform disconnected touchpoints into one continuously updated view of the complete customer journeyÂ
- Accelerate time-to-market for symposia content and capture HCP attention at the moment of highest engagement by producing targeted educational resources within days of data readoutsÂ
- Strengthen HCP relationships and boost engagement with relevant, compelling content at the exact moment it matters mostÂ
- Drive organizational agility by leveraging AI to harmonize fragmented data sources into connected strategic intelligence across all functionsÂ
- Strengthen customer engagement by designing connected journeys powered by AI-driven insights that predict and respond to evolving HCP needs in real timeÂ
- Accelerate decision-making by delivering on-demand, real-time analytics that enable medical and commercial teams to act faster without waiting for manual data requests or approvals
- Drive measurable business outcomes by translating shared insights into automated workflows that reduce time-to-action and improve consistency across functions
Â
Anindita Sinha, VP, Commercial Operations, Shionogi
Preethi Ramesh, Director - Data Digital & Technology, Takeda
- The blind spot in HCP targeting: Most targeting models are built on retrospective claims analysis — a record of where patients ended up, not how they actually experienced their disease. We'll examine why this backward-looking approach systematically misdirects commercial strategy.
- Clinical intent as the missing layer: Introducing clinical intent — a more holistic way to read disease experience and identify the right patient cohort before asking which HCPs to target, rather than reverse-engineering targeting from historical claims patterns.
- Operationalizing Patient First, Doctor Second: What this reordering means in practice — for data strategy, cohort definition, and how commercial teams should rethink the sequence of who they study first.
Â
Scott Phillips, Vice President, Real World Data Diaceutics, Diaceutics
- Eliminate the revision cycles that stall your commercial and medical teams through screening tools that cut approval timelines and get personalised content into the hands of field teams fasterÂ
- Build tiered approval frameworks that apply the right level of scrutiny to the right content, empowering your team to scale personalised, compliant customer engagement without the bottlenecks that slow impact
- Elevate engagement quality by fusing NBA precision with value-driven content strategies that address real customer priorities instead of relying solely on channel optimizationÂ
- Drive operational excellence by integrating omnichannel delivery, AI MLR acceleration and tiered approval systems into one cohesive personalization engine that scales impactÂ
- Drive strategic alignment by leveraging AI-powered intelligence layers that grant appropriate visibility to medical and commercial teams while respecting access protocols
- Optimize cross-functional performance by building data-sharing frameworks that eliminate silos without breaching regulatory separation requirements
Interactive workshop 1: From AI experiments to commercial impact: how intelligent data ecosystems are reshaping the pharma value chain Â
- Harness AI-enabled infrastructure and governed data intelligence to accelerate the transition from experimentation into compliant, scalable commercial executionÂ
- Strengthen medical-commercial collaboration through intelligent, cross-functional data sharing that surfaces actionable insights and drives measurable field impact at every stage of the commercial journeyÂ
Interactive workshop 2: From siloed to seamless: How data connectivity unlocks the real-world consumer, patient, and HCP journey
- Healthcare and pharma marketers have more data than ever — yet the consumer, patient, and HCP journey often remains fragmented across disconnected 1st, 2nd, and 3rd-party sources
- This session explores how data connectivity, not just data volume, is the key to overcoming that fragmentation
- Attendees will learn how securely linking owned, partner, and external data sources creates a unified, longitudinal view of the journey — from awareness through diagnosis, treatment, and prescribing behavior
- The discussion will cover what effective data connectivity requires in practice, and how organizations can translate a connected view into sharper targeting, better measurement, and superior real-world business outcomes
- Map the structural parallels between underrepresented leadership pathways in pharma and underrepresented customer voices in the healthcare ecosystem — identifying the shared patterns of "fewer peers, fewer channels, more friction"
- Translate personal leadership strategies — built from navigating rooms with limited access or sponsorship — into concrete tactics for building trust and influence with underserved HCP and patient populations
- Co-create at least one practical, cross-functional approach (commercial, medical, or engagement) that teams can pilot to authentically reach a specific underrepresented HCP or patient segment
- Commit to a personal or team-level action step — walking away with both a peer network and a concrete next move to bring back to their organization
- Legacy segmentation models were built for a world where frequency equalled impact — but as HCP access tightens and attention shrinks, are your targeting assumptions accelerating disengagement rather than preventing it?Â
- The field team of the future looks less like a rep and more like a trusted advisor armed with real-time behavioural intelligence — what needs to fundamentally change in your capabilities, culture, and processes to make that a reality?Â
Is your omnichannel strategy just multichannel with better branding — or are you personalizing at scale?Â
- Most omnichannel models still push content based on assumed preferences rather than real behavioural signals — are you genuinely orchestrating HCP journeys, or simply delivering the same message across more channels and calling it personalisation?Â
- When response signals tell you your content, timing, or channel mix isn't working, how quickly can your organisation act on that — and is your current feedback loop fast enough to matter in a market where HCP attention is the scarcest resource?Â
